Semaglutide Weight Management and Cardiovascular Risk Reduction
Diabetes is a serious chronic disease requiring treatment
intensification over time
Diabetes is associated with multiple
comorbidities
Despite many new treatment options,
many patients eventually need insulin
The burden of treatment may be a barrier
for good glycaemic control
Macrovascular
• Includes angina, CAD, MI,
stroke, PAD, CHF, and CKD
Microvascular
• Retinopathy
.
⚫ Nephropathy
Neuropathy
A 0.4% HbA1c reduction is associated
with reductions of¹:
10% death related to diabetes
7% all cause mortality
from PVD
• 21% amputation or death
B-cell function
Diet and exercise
Time
OAD
GLP-1
Insulin
• 50% of patients needing insulin delay
initiation by an average of 15 months due
to needle aversion, anxiety over insulin and
fear²
• >90% of physicians and patients have a
wish for good glycaemic control with insulin
not injected every day³
'Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study - PMC (nih.gov) - Linear relationship inferred, to estimate the point estimate with a 0.4% decrease in A1c. 2
Unpublished Novo Nordisk market research. ³Peyrot M et al. Diabet Med. 2012;29(5):682-689.
CAD: Coronary artery disease; MI: Myocardial infarction; PAD: Peripheral arteries disease; CHF: Congestive heart failure; CKD: Chronic kidney disease; OAD: Oral anti diabetics; GLP-1: Glucagon-like peptide-1; PVD: Peripheral vascular diseaseView entire presentation